These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26658793)

  • 1. Hospital Characteristics Associated with Stage II/III Rectal Cancer Guideline Concordant Care: Analysis of Surveillance, Epidemiology and End Results-Medicare Data.
    Charlton ME; Hrabe JE; Wright KB; Schlichting JA; McDowell BD; Halfdanarson TR; Lin C; Stitzenberg KB; Cromwell JW
    J Gastrointest Surg; 2016 May; 20(5):1002-11. PubMed ID: 26658793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline-Recommended Chemoradiation for Patients With Rectal Cancer at Large Hospitals: A Trend in the Right Direction.
    Del Vecchio NJ; Schlichting JA; Chioreso C; Kahl AR; Hrabe JE; Lynch CF; West MM; Charlton ME
    Dis Colon Rectum; 2019 Oct; 62(10):1186-1194. PubMed ID: 31490827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007.
    Haynes AB; You YN; Hu CY; Eng C; Kopetz ES; Rodriguez-Bigas MA; Skibber JM; Cantor SB; Chang GJ
    Cancer; 2014 Apr; 120(8):1162-70. PubMed ID: 24474245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node identification following neoadjuvant therapy in rectal cancer: A stage-stratified analysis using the surveillance, epidemiology, and end results (SEER)-medicare database.
    Ecker BL; Paulson EC; Datta J; Jeganathan AN; Aarons C; Kelz RR; Mahmoud NN
    J Surg Oncol; 2015 Sep; 112(4):415-20. PubMed ID: 26250884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
    Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
    Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing the optimum lymph node yield for diagnosis of stage III rectal cancer.
    Bhangu A; Kiran RP; Brown G; Goldin R; Tekkis P
    Tech Coloproctol; 2014 Aug; 18(8):709-17. PubMed ID: 24515286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital and Surgeon Selection for Medicare Beneficiaries With Stage II/III Rectal Cancer: The Role of Rurality, Distance to Care, and Colonoscopy Provider.
    Chioreso C; Gao X; Gribovskaja-Rupp I; Lin C; Ward MM; Schroeder MC; Lynch CF; Chrischilles EA; Charlton ME
    Ann Surg; 2021 Oct; 274(4):e336-e344. PubMed ID: 31714306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Diabetes and Other Clinical and Sociodemographic Factors With Guideline-concordant Breast Cancer Treatment for Breast Cancer.
    Gold HT; Shao H; Oratz R; Yu O; Hammer M; Richardson S; Boudreau D
    Am J Clin Oncol; 2020 Feb; 43(2):101-106. PubMed ID: 31850918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating Surveillance Patterns after Chemoradiation-Only Compared with Conventional Management for Older Patients with Rectal Cancer.
    Ellis CT; Cole AL; Sanoff HK; Hinton S; Dusetzina SB; Stitzenberg KB
    J Am Coll Surg; 2019 May; 228(5):782-791.e2. PubMed ID: 30685478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to treatment guidelines in stage II/III rectal cancer in Alberta, Canada.
    Eldin NS; Yasui Y; Scarfe A; Winget M
    Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):e9-17. PubMed ID: 21802914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
    Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB
    Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total Neoadjuvant Therapy With Short-Course Radiation: US Experience of a Neoadjuvant Rectal Cancer Therapy.
    Chapman WC; Kim H; Bauer P; Makhdoom BA; Trikalinos NA; Pedersen KS; Glasgow SC; Mutch MG; Silviera ML; Roy A; Parikh PJ; Hunt SR
    Dis Colon Rectum; 2022 Feb; 65(2):198-206. PubMed ID: 34990423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient survival after surgical treatment of rectal cancer: impact of surgeon and hospital characteristics.
    Etzioni DA; Young-Fadok TM; Cima RR; Wasif N; Madoff RD; Naessens JM; Habermann EB
    Cancer; 2014 Aug; 120(16):2472-81. PubMed ID: 24802276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
    Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
    Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of National Cancer Institute-designated cancer center status: observed variation in surgical care depends on the level of evidence.
    In H; Neville BA; Lipsitz SR; Corso KA; Weeks JC; Greenberg CC
    Ann Surg; 2012 May; 255(5):890-5. PubMed ID: 22504278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual treatment disparities after oncology referral for rectal cancer.
    Morris AM; Billingsley KG; Hayanga AJ; Matthews B; Baldwin LM; Birkmeyer JD
    J Natl Cancer Inst; 2008 May; 100(10):738-44. PubMed ID: 18477800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgeon-Level Variation in Utilization of Local Staging and Neoadjuvant Therapy for Stage II-III Rectal Adenocarcinoma.
    Swords DS; Skarda DE; Sause WT; Gawlick U; Cannon GM; Lewis MA; Scaife CL; Gygi JA; Tae Kim H
    J Gastrointest Surg; 2019 Apr; 23(4):659-669. PubMed ID: 30706375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Center Volume and Type Impact Stage-Specific Utilization of Neoadjuvant Therapy in Rectal Cancer.
    Midura EF; Jung AD; Daly MC; Hanseman DJ; Davis BR; Shah SA; Paquette IM
    Dig Dis Sci; 2017 Aug; 62(8):1906-1912. PubMed ID: 28501970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of outcomes between rectal squamous cell carcinoma and adenocarcinoma.
    Chiu MS; Verma V; Bennion NR; Bhirud AR; Li J; Charlton ME; Are C; Lin C
    Cancer Med; 2016 Dec; 5(12):3394-3402. PubMed ID: 27781400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population.
    Dobie SA; Warren JL; Matthews B; Schwartz D; Baldwin LM; Billingsley K
    Cancer; 2008 Feb; 112(4):789-99. PubMed ID: 18189291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.